Study of Efficacy and safety of alpha1 sympathetic receptor inhibitors for functional bowel disorders

Tsunaki Sawada0 个研究点目标入组 135 人开始时间: 2020年11月2日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who are diagnosed to Irritable Bowel Syndrome (IBS), Functional Constipation (FC), Functional Diarrhea (FD), Functional Bloating (FB), and Unclassified FBD ( Unspecified FBD: UFBD), in accordance with the Rome 4 criteria.
•20 years old and under 75 years old. It doesn't matter gender.
•In the case of females, only if there is no possibility of pregnancy in the interview, negative pregnancy reaction, and confirmation that no pregnancy has been attempted.
•Pateints who understand and agree with the research.

•Patients taking following medications (diuretics, azole antifungals, drugs with PGE5 inhibitory action).
•Patients who are taking antihypertensive drugs and have a history of orthostatic hypotension
•A case of internal treatment for benign prostatic hyperplasia.
•Case after surgical treatment for the digestive tract.
•Patients with liver function abnormalities (AST, ALT, gammaGT, ALP, LDH) are more than 1.5 times the facility standard value.(Those with already diagnosed mild liver dysfunction due to fatty liver or NASH can participate in the study.)
•Other cases with serious complications or abnormal laboratory values.
•Other cases where the investigator determines that participation in clinical studies is inappropriate.

发起方

Tsunaki Sawada